SCHEDULE 13G/A: Venrock Affiliates Reaffirm 6.4% Stake in 4D Molecular Therapeutics

Venrock Healthcare Capital Partners and its affiliated entities have filed an amendment to their Schedule 13G, confirming a continued 6.4% beneficial ownership in 4D Molecular Therapeutics, Inc. as of December 31, 2024.

Summary

• The filing is an Amendment No. 2 to Schedule 13G, reporting beneficial ownership of Common Stock in 4D Molecular Therapeutics, Inc.
• The reporting persons, including Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh, collectively beneficially own 2,952,371 shares.
• This aggregate amount represents 6.4% of 4D Molecular Therapeutics, Inc.'s Common Stock outstanding.
• The percentage is based on 46,227,709 shares of Common Stock outstanding as of November 12, 2024, as reported in the Issuer's Form 10-Q filed on November 13, 2024.
• All reporting persons share both voting and dispositive power over the 2,952,371 shares.
• The filing explicitly states that the securities were not acquired and are not held for the purpose or with the effect of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: The filing indicates continued significant passive ownership by a prominent healthcare investment group, suggesting ongoing confidence in the issuer. While not a major operational update, it reflects stability in the investor base.

Positives

• The continued significant beneficial ownership by Venrock Healthcare Capital Partners and its affiliates, a prominent healthcare investment group, signals ongoing confidence in 4D Molecular Therapeutics, Inc.'s long-term prospects.
• The passive nature of the investment, as stated in the filing, indicates that the investors are not seeking to influence or change control of the company, which can provide stability.

Future Outlook

This Schedule 13G/A filing does not contain any forward-looking statements or guidance regarding the issuer's future performance or strategic direction. It solely reports beneficial ownership.

Industry Context

This filing reflects a typical passive investment by a healthcare-focused private equity or venture capital firm in a biotechnology company. Such investments are common in the biotech sector, where specialized funds often take significant, but non-controlling, stakes in innovative companies like 4D Molecular Therapeutics, Inc. to support their growth and development.

Stakeholder Impact

• Shareholders may view the continued significant stake by Venrock affiliates as a positive signal of investor confidence and stability in the company's ownership structure.
• The passive nature of the investment suggests no immediate intent for activist intervention, which could be reassuring for current management and long-term investors.

Key Dates

Recommendation

Keywords

4D Molecular Therapeutics, Venrock Healthcare Capital Partners, Schedule 13G/A, beneficial ownership, common stock, institutional investment, biotechnology, gene therapy